Heron Therapeutics, Inc. HRTX, a biotechnology company, today
announced its intention to offer and sell shares of its common stock in an
underwritten offering pursuant to existing shelf registrations. All of the
shares in the proposed offering are to be sold by Heron Therapeutics, Inc.
Jefferies LLC, Leerink Partners LLC and Cowen and Company, LLC are acting as
joint book-runners for the offering. Heron Therapeutics, Inc. intends to
grant the underwriters a 30-day option to purchase additional shares of its
common stock. The offering is subject to market conditions, and there can be
no assurance as to whether or when the offering may be completed, or the
actual size or terms of the offering.
Heron Therapeutics, Inc. intends to use the net proceeds from the
underwritten offering primarily for general corporate purposes, which
include, but are not limited to, the commercial launch of SUSTOL(R)
(granisetron injection, extended release), if approved by the FDA, funding
the company's ongoing and future clinical trials, preclinical development
work, and for general and administrative expenses, or other product
development activities.
The securities described above are being offered pursuant to shelf
registration statements (File Nos. 333-195928 and 333-198862), which were
declared effective by the United States Securities and Exchange Commission
("SEC") on May 23, 2014 and October 6, 2014, respectively. The securities
described above have not been qualified under any state blue sky laws. This
press release shall not constitute an offer to sell or the solicitation of
an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction. The offering can be made only by means of a prospectus, copies
of which may be obtained at the SEC's website at www.sec.gov, or by request
at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520
Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340,
e-mail: Prospectus_Department@Jefferies.com.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in